Comparison of the efficacy of dapagliflozin and linagliptin in the treatment of type 2 diabetes patients with normal body mass index and poor metformin monotherapy
| Autor: | Mingli He, Li Jiang, Su Zhang, Xinrong Yang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Traditional Medicine and Modern Medicine, Vol 07, Iss , Pp 85-91 (2024) |
| Druh dokumentu: | article |
| ISSN: | 25759000 2575-9019 2575-9000 |
| DOI: | 10.1142/S2575900024500058 |
| Popis: | Objective: To explore the efficacy and safety of dapagliflozin and linagliptin in the treatment of type 2 diabetes patients (T2DM) with normal body mass index (BMI) who have poor single drug efficacy of metformin. Method: 102 T2DM patients with normal BMI who visited our hospital from December 2021 to March 2023 were randomly divided into an observation group (51 cases) and a control group (51 cases) using a random number table method. The control group patients were treated with linagliptin in addition to metformin treatment, while the observation group was treated with dapagliflozin in addition to metformin treatment. The general indicators, blood glucose metabolism, biochemical indicators, and adverse reactions of the two groups of patients were compared. Result: After treatment, the body weight and BMI of both the observation group and the control group slightly decreased, while the systolic blood pressure of the observation group decreased. The changes in systolic blood pressure of the control group were not significant, and the differences were not statistically significant ([Formula: see text]); after treatment, the fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) of both groups of patients decreased, and the FPG and HbA1c of the control group were not significantly lower than those of the observation group ([Formula: see text]). After treatment, the values of blood creatinine, blood uric acid, urinary microalbumin (UAlb), and urinary microalbumin/creatinine (UACR) in both groups of patients decreased, and the decrease in various biochemical indicators in the control group was not as significant as that in the observation group. The comparison of blood uric acid, UAlb, and UACR between the two groups showed statistical significance ([Formula: see text]). The incidence of adverse reactions in the observation group and control group patients was 8.70% and 13.04%, respectively, and there was no statistically significant difference ([Formula: see text]) after comparison. Conclusion: Both dapagliflozin and linagliptin have shown good efficacy in the treatment of T2DM patients with normal BMI and poor efficacy in monotherapy with metformin. Compared to linagliptin, dapagliflozin can cause slight weight loss in patients, but its control effect on blood glucose and blood pressure is better than that of linagliptin. The risk of hypoglycemia is lower, and it has a protective effect on the kidneys. The disadvantage is that it slightly increases the risk of urogenital tract infections, Overall, it has high security and can be promoted for use. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|